C12N 2310/11
Antisense
C12N2310/11 (Antisense) appears on 4,701 US grants and 9,327 published applications in this corpus.
Search patents in C12N- Granted patents
- 4,701
- Published applications
- 9,327
- Assignees
- 2,234
- Inventors
- 11,789
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 6 | 0 |
| 1993 | 9 | 0 |
| 1994 | 6 | 0 |
| 1995 | 10 | 0 |
| 1996 | 7 | 0 |
| 1997 | 45 | 0 |
| 1998 | 57 | 0 |
| 1999 | 74 | 0 |
| 2000 | 63 | 0 |
| 2001 | 46 | 10 |
| 2002 | 49 | 58 |
| 2003 | 31 | 154 |
| 2004 | 32 | 194 |
| 2005 | 13 | 282 |
| 2006 | 38 | 220 |
| 2007 | 33 | 255 |
| 2008 | 46 | 235 |
| 2009 | 92 | 316 |
| 2010 | 145 | 341 |
| 2011 | 160 | 341 |
| 2012 | 216 | 353 |
| 2013 | 205 | 327 |
| 2014 | 253 | 377 |
| 2015 | 286 | 518 |
| 2016 | 285 | 469 |
| 2017 | 294 | 420 |
| 2018 | 278 | 439 |
| 2019 | 316 | 433 |
| 2020 | 281 | 461 |
| 2021 | 257 | 510 |
| 2022 | 268 | 529 |
| 2023 | 215 | 540 |
| 2024 | 223 | 569 |
| 2025 | 198 | 581 |
| 2026 | 160 | 395 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- ß-amyloid cyclic ribonucleic acid, polypeptide, and application thereof6 Oct 2026US 12,753,215 B2
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement6 Oct 2026US 12,753,411 B2The Brigham and Women S Hospital, Inc.
- Methods for X chromosome reactivation29 Sep 2026US 12,746,254 B2The Regents of the University of California
- Composition and Method for Topical Trans-spinal Delivery of Nucleic Acids and Small Molecules8 Oct 2026US 2026/0306414 A13P Biotechnologies, Inc.
- Optimized gapmers antisense oligonucleotides for increasing foxg1 expression8 Oct 2026US 2026/0308582 A1EliGab Tx LLC
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)8 Oct 2026US 2026/0308585 A1Alnylam Pharmaceuticals, Inc.
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods496US 4,987,071 AUniversity Patents, Inc. · 1991
- Anti-sense regulation of gene expression in plant cells354US 5,107,065 ACalgene, Inc. · 1992